BioStem Technologies, Inc. (BSEM)
| Market Cap | 54.80M |
| Revenue (ttm) | 34.59M -49.1% |
| Net Income | -28.29M |
| EPS | -1.67 |
| Shares Out | 17.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,839 |
| Open | 3.100 |
| Previous Close | 3.090 |
| Day's Range | 3.040 - 3.241 |
| 52-Week Range | 2.251 - 8.400 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About BSEM
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a hu... [Read more]
Financial Performance
Financial StatementsNews
BioStem Technologies announces USPTO issued 1 patent, 3 notices of allowance
BioStem Technologies (BSEM) announced that the United States Patent and Trademark Office, USPTO, has issued one patent and three notices of allowance for additional patent applications and the Mexican...
BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manuf...
BioStem Technologies prices 735,296 shares at $4.08 in private placement
BioStem Technologies (BSEM) announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the company’s common stock, Series A warrants to purchase up…
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manuf...
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 ...
BioStem Technologies files to sell 12.05M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 12.05M shares of common stock. The company is not selling any…
BioStem Technologies Registration statement: Registration filing
BioStem Technologies filed a registration statement on September 18, 2026, providing details about a securities offering with the SEC.
BioStem Technologies Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company completed a major acquisition and Nasdaq uplisting, shifting focus to surgical biologics and expanding its commercial team. Manufacturing transfer in 2027 is expected to boost margins, while the launch of a 510(k)-cleared product should accelerate growth. Key goals include strengthening the balance sheet and hitting raised guidance.
BioStem Technologies reports GPO contract coverage for Vendaje, Vendaje AC
BioStem Technologies (BSEM) announced that Vendaje and Vendaje AC have been added to the company’s existing contracts with Vizient and Premier., two group purchasing organizations. The products are av...
BioStem Technologies Transcript: Micro-Cap Virtual Conference
A strategic shift to a surgical-centric model, expanded board, and Nasdaq uplisting have positioned the company to target a $26 billion market with a diversified, clinically proven product portfolio. Sequential revenue growth, margin recovery plans, and strong clinical evidence support a positive outlook.
BioStem Technologies Slides: Company presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2026.
BioStem Technologies Earnings Call Transcript: Q2 2026
Revenue grew to $7.9M in Q2 2026, driven by hospital segment expansion and commercial investments. Gross margin held at 61%, with guidance raised to $26–$29M for the year. Uplisting to Nasdaq and new patents support growth, while a $10M milestone payment is pending.
BioStem Technologies Quarterly report: Q2 2026
BioStem Technologies has published its Q2 2026 quarterly earnings report on August 12, 2026.
BioStem Technologies Earnings release: Q2 2026
BioStem Technologies released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
BioStem files registration statement with SEC, to pursue Nasdaq listing
BioStem Technologies (BSEM) announced the filing of a Form 10 registration statement with the SEC to register its shares of common stock pursuant to the Securities Exchange Act of 1934,…
BioStem Technologies issued four U.S. design patents for allograft technology
BioStem Technologies (BSEM) announced that the USPTO has issued four U.S. design patents covering the company’s proprietary fenestrated human placental allograft technologies. The four patents further...
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies
Company Continues to Expand Intellectual Property Portfolio Supporting Advanced Placental Allograft Innovation POMPANO BEACH, FL / ACCESS Newswire / July 8, 2026 / BioStem Technologies, Inc. (OTCID:BS...
BioStem Technologies announces notice of allowance for four patents
BioStem Technologies (BSEM) announced that the United States Patent and Trademark Office, or USPTO, has issued notices of allowance for four new divisional U.S. design patent applications related to i...
BioStem Technologies price target lowered to $7 from $9 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on BioStem Technologies (BSEM) to $7 from $9 and keeps a Buy rating on the shares. The firm said that the physician-office channel…
Biostem Technologies initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of Biostem Technologies (BSEM) with a Buy rating and $9 price target While the decline in industry revenues has resulted in depressed ...
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Le...
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
BioTissue Deepens Commitment to Ocular Market Leadership MIAMI, Jan. 21, 2026 /PRNewswire/ -- BioTissue Holdings, Inc, a leader in harnessing the unique properties of human birth tissue to facilitate ...
BioStem Technologies Slides: Conference presentation
BioStem Technologies has posted slides in relation to its latest quarterly earnings report, which was published on January 10, 2026.
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
POMPANO BEACH, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercializatio...
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...